Clearmind Medicine Inc.

Equities

CMND

CA1850535016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-12 pm EST			5-day change	1st Jan Change
2.160 ^USD	-8.09%		-13.25%	+19.34%

Dec. 31	Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule	MT
Dec. 16	Clearmind Medicine announces successful completion of second cohort enrollment	RE

Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder

Published on 12/02/2025 at 02:20 pm EST

S&P Capital IQ

Clearmind Medicine Inc.

-8.09%

Clearmind Medicine Inc. announced another key milestone in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AUD): the first participant has been enrolled and dosed with CMND-100, its proprietary MEAI-based oral drug candidate, at Hadassah- University Medical Center in Jerusalem, Israel. The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco, Director of the Clinical Pharmacology Unit in the Department of Medicine. This site is part of the Company's multinational Phase I/IIa clinical study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with AUD.

Recent positive top-line results from the first cohort and unanimous Data and Safety Monitoring Board recommendation that the clinical trial continue contribute to supporting strong momentum across all active sites.

Latest news about Clearmind Medicine Inc.

Dec. 31	Clearmind Medicine Says Nasdaq Compliance Regained on Minimum Bid Price Rule	MT
Dec. 16	Clearmind Medicine announces successful completion of second cohort enrollment	RE
Dec. 16	Clearmind Medicine Announces Successful Completion of Second Cohort Enrollment in Ongoing FDA-Approved Phase I/IIa Trial for CMND-100	CI
Dec. 12	Clearmind Medicine Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement	MT
Dec. 03	Clearmind Medicine Inc files for offering of up to 16 million common shares - SEC filing	RE
Dec. 02	Clearmind Medicine Advances CMND-100 to Dosing Phase at Hadassah Medical Center in Ongoing Phase I/IIa Clinical Trial for Alcohol Use Disorder	CI
Dec. 02	Clearmind Medicine advances CMND-100 to dosing phase at Hadassah Medical Center	RE
Dec. 01	Clearmind advances alcoholism treatment with positive data, DSMB approval, and new trial site	RE
Dec. 01	Clearmind Medicine Inc. Announces Three Transformative Milestones in its FDA- Approved Phase I/IIa Clinical Trial for CMND-100	CI
Nov. 25	Clearmind Medicine Kicks-Off Patient Enrollment At Tel Aviv Sourasky Medical Center, Adding Another Site Activated in Its in Phase I/IIa Alcohol Use Disorder Trial	CI
Nov. 24	Clearmind Medicine's Data and Safety Monitoring Board Unanimously Approves Continuation of Phase I/Iia Clinical Trial for Cmnd-100 Following Positive Interim Safety Review	CI
Nov. 20	Neurothera Labs Inc. Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression	CI
Nov. 20	Clearmind Medicine Accelerate Fda-Approved Alcohol Use Disorder Clinical Trial by Activating Fifth Elite Global Medical Site	CI
Nov. 18	Clearmind Medicine announces positive top-line results from first cohort of its FDA-approved Phase I/IIa clinical trial for alcohol use disorder	RE
Nov. 18	Clearmind Medicine Announces Positive Top-Line Results from First Cohort of Its Fda-Approved Phase I/Iia Clinical Trial for Alcohol Use Disorder	CI
Nov. 17	Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression	CI
Nov. 13	Clearmind Medicine Gets Final Approval for Psychedelic-Based Alcohol Use Disorder Trial in Israel	MT
Nov. 13	Clearmind Medicine Inc. Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center	CI
Nov. 12	Clearmind Medicine Inc. Announces Notice of Patent Publication for Depression Treatment	CI
Nov. 10	Clearmind Medicine Inc. Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder	CI
Nov. 05	Clearmind Medicine Inc. Expands Global Ip Protection for Meai in Depression Treatment with New South Korea Patent Filing	CI
25-10-31	Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy	CI
25-10-30	Clearmind Medicine Completes First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder	CI
25-10-27	Clearmind Medicine Inc Appoints Mary-Elizabeth Gifford as Chief of Global Impact	CI
25-10-21	Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder	CI

Chart Clearmind Medicine Inc.

Duration

Period

CMND: Dynamic Chart

Company Profile

Clearmind Medicine Inc. is a psychedelic pharmaceutical biotech company. The Company is focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorders. The Company researches and develops psychedelic-based compounds and attempts to commercialize them as regulated medicines, foods, or supplements. The Companyâs intellectual portfolio consists of 15 patent families, including 27 granted patents and 24 pending applications. The portfolio spans a range of jurisdictions, including the United States, Europe, India, and China.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 02 - Q4 2025 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data